Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
- 210 Downloads
Objective To determine the recommended dose for phase II trials of elisidepsin (PM02734, Irvalec®) in combination with erlotinib in patients with advanced malignant solid tumors. Methods Open-label, dose-escalating, phase I study of intravenous elisidepsin administered weekly (days 1, 8 and 15) over 3 h as a flat dose (FD) and daily oral erlotinib, every 3 weeks. A pharmacokinetic analysis was done on blood samples collected around the first elisidepsin infusion. Results Thirty patients were treated across six different dose levels (DLs) ranging from elisidepsin 0.33–2.25 mg/erlotinib 100–150 mg. Two patients had dose-limiting toxicities: grade 3 bilirubin increase (DL3: 0.75 mg/150 mg) and a dose omission for > 2 weeks due to grade 3 alanine aminotransferase increase (DL6: 2.25 mg/100 mg). The daily erlotinib dose was escalated to 150 mg at DL2-DL5, but decreased to 100 mg at DL6, as most grade 3 toxicities were related to this agent only. The most frequent toxicities were transaminase increases (related to elisidepsin), and rash, pruritus and diarrhea (related to erlotinib). No objective responses were observed. Despite no overlapping toxicities, the combination was declared unfeasible due to frequent elisidepsin dose delays. The pharmacokinetics of elisidepsin/erlotinib was not significantly different from that of each agent alone. Conclusion The difficulty in combining elisidepsin with the standard dose of erlotinib (150 mg), together with the lack of antitumor activity, made the combination unattractive for further development. The trial was closed without having determined a recommended dose.
KeywordsPM02734 Phase I Erlotinib Combination Dose-limiting toxicities
We thank all the staff who contributed to the care of the patients included in this study.
Compliance with ethical standards
Conflict of interest
Cinthya Coronado, Eva M. Fernández-García, Jorge Luis Iglesias Dios and Bernardo Miguel-Lillo are employees of Pharma Mar.
- 7.Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J et al (2011) PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin Cancer Res: Off J Am Assoc Cancer Res 17(16):5353–66CrossRefGoogle Scholar
- 9.Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY et al. (2015) Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. OncotargetGoogle Scholar
- 14.Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N et al (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65(20):9455–62PubMedCrossRefGoogle Scholar
- 17.Buck EA, Eyzaguirre A, Gibson N, Cagnoni P, Haley JD, Iwata KK (2005) Identification of E-cadherin and HER3 as biomakers of sensitivity to the EGFR kinase inhibitor erlotinib in pancreatic and colorectal cancers. In: Proceedings of the AACR-NCI-EORTC International Conference. Molecular Targets and Cancer Therapeutics. Poster Session B: Biological Therapeutic Agents: Growth Factor Receptors and Other Surface Antigens as Targets for Therapy; Philadelphia, p. 142- Poster B66Google Scholar
- 19.Salazar R, Metges JP, Anthoney DA, Laus G, Maqueda MA, Goncalves A et al. (2013) IMAGE, a randomized phase Ib/II study of elisidepsin (E) as a single agent in pretreated advanced gastroesophageal (GE) cancer. 2013 Gastrointestinal Cancers Symposium, Jan 24–26, 2013. San Francisco, California. J Clin Oncol 31(4 Supl) Abs N 92Google Scholar
- 21.Bruce JY, Geary D, de las Heras B, Soto A, Garcia Paramio P, Yovine A et al. (2008) Phase I study of PM02734: association of dose-limiting hepatotoxicity with plasma concentrations. ASCO American Society of Clinical Oncology, 44th Annual Meeting, May 30- Jun 3, 2008. Chicago. Abs. N°2513Google Scholar
- 25.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–16PubMedCrossRefGoogle Scholar
- 27.Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL et al (2015) First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Investig New Drugs 33(4):901–10CrossRefGoogle Scholar
- 28.National Cancer Institute Common Terminology Criteria for Adverse Events. Version 3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed 10 July 2008
- 32.Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 23(25):5892–9CrossRefGoogle Scholar
- 33.Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol: Off J Am Soc Clin Oncol 25(12):1545–52CrossRefGoogle Scholar
- 35.Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol: Off J Am Soc Clin Oncol 19(13):3267–79Google Scholar